跳至主要内容
临床试验/EUCTR2017-001679-22-NL
EUCTR2017-001679-22-NL进行中(未招募)1 期

Randomized, double blind, placebo controlled, multicenter pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure - EMPA-RESPONSE-AHF

niveristy Medical Center Groningen0 个研究点目标入组 80 人开始时间: 2017年9月7日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •1. Male or female >18 years of age;
  • •2. Hospitalized for AHF; AHF is defined as including all of the followings measured at any time between presentation (including the emergency department) and the end of screening:
  • •a. Dyspnea at rest or with minimal exertion
  • •b. Signs of congestion, such as edema, rales, and/or congestion on chest radiograph
  • •c. BNP =350 pg/mL or NT-proBNP =1,400 pg/mL (for patients with AF: BNP=500 pg/mL or NT-proBNP =2,000 pg/mL)
  • •d. Treated with loop diuretics at screening
  • •3. Able to be randomized within 24 hours from presentation to the hospital
  • •4. Able and willing to provide freely given written informed consent
  • •5. eGFR (CKD-EPI) =30 ml/min/1.73m2 between presentation and randomization
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 20
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 60

排除标准

  • •1. Dyspnea primarily due to non-cardiac causes
  • •2. Cardiogenic shock
  • •3. Acute coronary syndrome within 30 days prior to randomization
  • •4. Planned or recent percutaneous or surgical coronary intervention within 30 days prior to randomization
  • •3. Signs of keto-acidosis and/or hyperosmolar hyperglaecemic syndrome (pH>7.30 and glucose >15 mmol/L and HCO3>18 mmol/L)
  • •4. Pregnant or nursing (lactating) women
  • •5. Current participation in any interventional study
  • •6. Inability to follow instructions or comply with follow-up procedures
  • •7. Any other medical conditions that may put the patient at risk or influence study results in the investigator’s opinion, or that the investigator deems unsuitable for the study.

研究者

发起方
niveristy Medical Center Groningen

相似试验

已完成
2 期
Randomized, double blind, placebo controlled, multicenter pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure'Acute Heart Failure'10082206
NL-OMON46516niversitair Medisch Centrum Groningen80
进行中(未招募)
不适用
Randomized, placebo controlled, double blind, multi-center phase II proof-of-concept study to assess the efficacy of AIN457 in patients with moderate to severe ankylosing spondylitis - CAIN457A2209Ankylosing Spondylitis (AS), which belongs to seronegative spondyloarthropathies (SpA).MedDRA version: 9.1Level: LLTClassification code 10002556Term: Ankylosing spondylitis
EUCTR2008-002631-33-GBovartis Pharma Services AG30
进行中(未招募)
不适用
Randomized, placebo controlled, double blind, multi-center phase II proof-of-concept study to assess the efficacy of AIN457 in patients with moderate to severe ankylosing spondylitis - A2209Ankylosing Spondylitis (AS), which belongs to seronegative spondyloarthropathies (SpA).MedDRA version: 9.1Level: LLTClassification code 10002556Term: Ankylosing spondylitis
EUCTR2008-002631-33-DEovartis Pharma Services AG60
进行中(未招募)
1 期
Study to evaluate the efficacy and safety of givinostat in ambulant patients with Duchenne Muscular Dystrophy.Duchenne Muscular Dystrophy (DMD)MedDRA version: 19.1Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disorders
EUCTR2016-000401-36-ITITALFARMACO S.p.A.192
进行中(未招募)
1 期
Study to evaluate the efficacy and safety of givinostat in ambulant patients with Duchenne Muscular Dystrophy.Duchenne Muscular Dystrophy (DMD)MedDRA version: 19.1Level: PTClassification code 10013801Term: Duchenne muscular dystrophySystem Organ Class: 10010331 - Congenital, familial and genetic disorders
EUCTR2016-000401-36-ESITALFARMACO S.p.A.192